Out in the Light

During the first six months of 2009, Pfizer paid about $20 million to some 4,500 medical professionals in consulting and speaking fees, reports the New York Times. In addition, Pfizer paid $15.3 million to 250 academic medical centers for clinical trials. These details were released as part of an agreement Pfizer made with the US government during an investigation into the company's promotion of drugs for off-label uses. Eli Lilly, Merck, and GlaxoSmithKline have made similar disclosures.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

In a survey, about half of Canadian government scientists say they still feel as though they cannot speak freely, ScienceInsider reports.

The Atlantic reports that biohacker Josiah Zayner regrets injecting himself with the CRISPR gene-editing tool on stage.

Clinicians in China are moving ahead with a number of CRISPR trials, NPR reports, as the US embarks on its first.

In Nature this week: genomic approaches applied to study Neolithic and Bronze Age Europeans, and more.